Germline BRCA1/BRCA2 Testing in Breast Cancer: A Predictive Biomarker

Why this test matters

A patient with newly diagnosed triple-negative breast cancer, aged forty-two, asks whether her diagnosis was inherited — and whether it changes her treatment. That single question now sits at the intersection of oncology, surgery, genetic counseling, and pathology, and the germline BRCA1/BRCA2 test is what begins to answer it. What was once framed almost entirely as a question of familial cancer risk has, over the past several years, become a predictive biomarker: a result that helps determine which classes of drug a patient may be eligible for.

That dual role — hereditary risk assessment and therapeutic eligibility — is what makes germline BRCA testing distinctive. The same blood or saliva sample that flags a family cancer syndrome also opens or closes the door to a specific drug class. So it's worth understanding precisely what the assay measures, what each result means, and where the evidence is still settling.

The biology, briefly

BRCA1 and BRCA2 encode proteins essential to homologous recombination repair — the high-fidelity system cells use to mend double-strand DNA breaks. When one inherited (germline) copy carries a pathogenic variant and the tumor loses the second, functional copy, the cancer cell can no longer repair those breaks accurately. It becomes dependent on more error-prone backup pathways.

That dependency is the therapeutic opening. PARP inhibitors block an enzyme involved in single-strand break repair; in a cell already crippled for homologous recombination, that second hit is often lethal. This is the principle of synthetic lethality — two individually survivable defects that together kill the cell. It's an elegant piece of tumor biology, and it explains why a germline finding predicts drug sensitivity rather than merely describing inherited risk.

The two genes aren't interchangeable. BRCA1-associated breast cancers skew toward triple-negative, high-grade, hormone-receptor–negative disease, while BRCA2-associated tumors more often present as hormone-receptor–positive. That phenotypic difference matters clinically, but for the purposes of PARP-inhibitor eligibility, a pathogenic variant in either gene carries weight.

How the test is performed

The specimen is germline material — blood or saliva — which reflects the DNA a patient was born with in every cell. That's a crucial distinction from tumor (somatic) sequencing, which interrogates DNA from the cancer itself. A germline test asks: did this person inherit a BRCA variant? A somatic test asks: does this tumor carry one, however it arose? The two questions overlap but aren't the same, and confusing them leads to real errors in counseling.

The assay is sequencing of the BRCA1 and BRCA2 genes, typically supplemented by methods that detect large deletions and duplications, since some pathogenic events are copy-number changes rather than single-base substitutions. Because the sample is germline, preanalytic constraints are relatively forgiving compared with tumor tissue — there's no concern about fixation artifact or tumor cellularity — but sample identity and contamination controls still matter.

Scoring follows a variant-classification framework. Each detected variant is graded, and for clinical decision-making the meaningful line is drawn between pathogenic or likely pathogenic variants on one side and everything else on the other. The two reportable result states that drive management are: pathogenic (or likely pathogenic) variant present, or no pathogenic variant identified.

What each result means

A pathogenic or likely pathogenic variant confirms a germline BRCA1 or BRCA2 alteration. This carries implications on two fronts: it identifies a hereditary cancer predisposition relevant to the patient and potentially to blood relatives, and — the predictive part — it establishes eligibility for a defined drug class.

No pathogenic variant identified means no actionable germline BRCA alteration was found. In the predictive framework, that result doesn't gate PARP-inhibitor eligibility on a germline basis. It doesn't, however, exclude other homologous-recombination defects or somatic BRCA events, and it doesn't rule out variants in genes not covered by the assay.

Then there's the middle category that trips people up: the variant of uncertain significance (VUS). A VUS is not a positive result. In practice, for the patient sitting in the clinic, a VUS should be treated as non-actionable — it neither confirms hereditary risk nor establishes drug eligibility, and clinicians should resist the temptation to manage it as though it were pathogenic. VUS classifications can and do change over time as evidence accumulates, which is why reputable laboratories reclassify variants and reissue reports.

What it determines for treatment eligibility

Here the predictive value becomes concrete. A confirmed germline pathogenic BRCA variant informs eligibility for the PARP-inhibitor class.

In the adjuvant setting — early breast cancer after primary treatment — the OlympiA trial demonstrated a benefit for olaparib in patients with germline BRCA1/2 pathogenic variants and high-risk HER2-negative disease [1]. In metastatic disease, OlympiAD established olaparib [2] and EMBRACA established talazoparib [3] as options for patients with a germline BRCA mutation and HER2-negative advanced breast cancer, each demonstrating improved progression-free survival versus standard chemotherapy.

Worth noting: these trials required confirmed germline pathogenic variant status at enrollment. That design choice isn't incidental. The synthetic-lethality rationale only holds when the underlying repair defect is genuinely present, so the trials selected their populations up front by variant status rather than testing after the fact. That's precisely why the biomarker result functions as a gate — the evidence base was built on patients defined by it.

Beyond drug eligibility, a germline pathogenic result also informs discussion of risk-reducing surgery. That's a shared decision-making conversation, well outside anything a pathology report prescribes, but the test result is what makes the conversation relevant.

To be clear, none of this amounts to treatment advice for any individual. A biomarker result establishes eligibility for a drug class; whether a given patient receives a given drug is a clinical decision made in context.

Caveats and what's evolving

A few points deserve flagging. First, the germline-versus-somatic distinction continues to matter as somatic BRCA testing gains ground — a tumor may harbor a somatic BRCA alteration even when the germline test is negative, and the therapeutic relevance of that scenario is an area of active study. Second, the pivotal trials defined eligibility in HER2-negative populations, so the emergence of HER2-low as a distinct category is worth watching as the evidence matures. Third, variant classification is not static; a "no pathogenic variant" or VUS result reflects knowledge at the time of reporting.

For the patient who leaves the clinic with a VUS, the practical message is steadiness: it's not a positive result today, it may be reclassified in either direction tomorrow, and the reflex to act on ambiguity does more harm than good. Periodic re-review of an uncertain variant, rather than premature action, is where the discipline lies.

References

1. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients With BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021. doi:10.1056/NEJMoa2105215
2. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation. N Engl J Med. 2017. doi:10.1056/NEJMoa1706450
3. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients With Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018. doi:10.1056/NEJMoa1802905